YK-2168

N/A

Report date: 2023/05/10 20:00:50
NME

Base Information

Drug NameYK-2168
Drug Alias NameYK-2168
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitors
TargetsCyclin-dependent kinase 9
Therapy Area/IndicationsSolid tumoursLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Yoko Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Damei biopharmaceutical Co LtdNanjing Yoko Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A